Therapeutic Indications:Pathogenetic therapy of cytokine release syndrome in patients with moderate to severe new coronavirus infection (COVID-19).
1Criteria for prescribing according to the Temporary guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" of the Ministry of Health of the Russian Federation (version 17 of 14.12.2022 in Russ.)2:Adult patients with mild to moderate COVID-19 and risk factors of severe course, with CT 1-2 or moderate pneumonia
3, in combination with two or more of the following symptoms:
• SpO2 – 97% or higher, no signs of shortness of breath
• 3N ≤ CRP ≤ 6N;
• fever 37,5-37,9°С for 3-5 days;
• white blood cell count – 3,5-4,0*10
9/l;
• absolute lymphocyte count – 1,5-2,0*10
9/l
Adult patients with CT 1-2 or moderate pneumonia3, in combination with two or more of the following symptoms:
• SpO2 – 94%-97%, shortness of breath on exertion
• 6N ≤ CRP < 9N;
• fever ≥ 38°С for 3-5 days;
• white blood cell count – 3,0-3,5*10
9/l;
• absolute lymphocyte count – 1,0-1,5*10
9/l
Adult patients with CT 1-4 or moderate3 to severe4 pneumonia, in combination with two or more of the following symptoms:
• SpO2 ≤ 93% dyspnea at rest / progressive dyspnea during the first 2-3 days
• fever >38°С for 2-3 days;
• CRP ≥ 9N or an increase in CRP levels by 3 times for 3-5 days of illness;
• white blood cell count < 3,0*10
9/l;
• absolute lymphocyte count < 1,0*10
9/l
• Serum ferritin level* ≥ 2 normal for 3-5 days of illness
• Serum LDH level ≥ 1.5 norms for 3-5 days of illness
• IL-6 level* > 40 pk / ml.
Posology and method of administration:Mild:64 mg (1 vial 160 mg/mL, 0,4 мл) subcutaneously1,2If there is an insufficient effect, repeat the injection intravenously after 24 hours. In total, no more than 256 mg should be administered.**
Moderate**:64 – 128 mg (1 or 2 vials of 160 mg/mL, 0,4 mL) intravenouslyDilute in 100 mL of 0.9% NaCl solution (duration – 60 minutes). If there is an insufficient effect, repeat the injection intravenously after 24 hours. In total, no more than 256 mg should be administered.
Severe and critical**:256 mg (4 vials of 160 mg/mL, 0,4 mL) intravenouslyDilute in 100 mL of 0.9% NaCl solution (duration – 60 minutes).
* Serum ferritin and IL-6 levels are determined when studies are held ** This method is not included in full prescribing information for Olokizumab. According to Temporary guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" of the Ministry of Health of the Russian Federation (version 13.1 of 17/11/2021) (in Russ.)1. Instruction for the medical use of Artlegia, ЛП-006218 dated May 21, 2020, the owner of the registration certificate – R-Pharm JSC2. Temporary guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" of the Ministry of Health of the Russian Federation (version 17 of 14/12/2022) (in Russ.)3. According to the X-ray examination: homogeneous blackening of round shape and different extent, involvement of lung parenchyma ≤ 50%4. According to the X-ray examination: blackening by type of infiltration (symptom of "white lungs") involvement of lung parenchyma ≥ 50%